BIOMARKERS FOR STROKE
First Claim
Patent Images
1. A method for diagnosing stroke in a subject comprising:
- (a) measuring the level of one or more biomarkers in a sample from the subject;
(b) comparing the level of the one or more biomarkers to a reference level of the one or more biomarkers;
wherein the one or more biomarkers comprise gene products expressed from genes selected from the group consisting of IL-1α
, IL-1β
, IL-1ra, IL-3, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17, EGF, Eotaxin, FGF-2, FTL-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α
2, IFN-γ
, IP-10, MCP-1, MCP-3, MCD, MIP-1α
, MIP-1β
, PDGF-aa, PGDF-aa bb, RANTES, sCD40L, sIL2-rα
, TNF-α
, TNF-β
, VEGF and genes listed in Tables 4, 5, 6 and 8.
1 Assignment
0 Petitions
Accused Products
Abstract
Biomarkers for stroke and methods for their detection are disclosed. In one aspect, the present application discloses biomarkers for the diagnosis of stroke in a subject. In another aspect, the application discloses a method for the diagnosis of stroke in a subject. The method comprises detection of stroke biomarkers in cerebrospinal fluid, blood, serum or PMBCs of a subject. Also disclosed is a kit for the detection of biomarkers for the diagnosis of stroke in a subject.
65 Citations
20 Claims
-
1. A method for diagnosing stroke in a subject comprising:
-
(a) measuring the level of one or more biomarkers in a sample from the subject; (b) comparing the level of the one or more biomarkers to a reference level of the one or more biomarkers; wherein the one or more biomarkers comprise gene products expressed from genes selected from the group consisting of IL-1α
, IL-1β
, IL-1ra, IL-3, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17, EGF, Eotaxin, FGF-2, FTL-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α
2, IFN-γ
, IP-10, MCP-1, MCP-3, MCD, MIP-1α
, MIP-1β
, PDGF-aa, PGDF-aa bb, RANTES, sCD40L, sIL2-rα
, TNF-α
, TNF-β
, VEGF and genes listed in Tables 4, 5, 6 and 8. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method for determining disease progression in a subject after a stroke, comprising:
-
(a) measuring the level of one or more biomarkers in a first sample obtained from the subject at a first time point; (b) measuring the level of the one or more biomarkers in a second sample obtained from the subject at a second time point; (c) comparing the level of the one or more biomarkers at the first time point to the level of the one or more biomarkers at the second time point; and (d) determining the disease progression between the first and the second time point based on the result of step (c), wherein the one or more biomarkers comprise gene products expressed from genes selected from the group consisting of IL-1α
, IL-1β
, IL-1ra, IL-3, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17, EGF, Eotaxin, FGF-2, FTL-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α
2, IFN-γ
, IP-10, MCP-1, MCP-3, MCD, MIP-1α
, MIP-113, PDGF-aa, PGDF-aa bb, RANTES, sCD40L, sIL2-rα
, TNF-α
, TNF-β
, VEGF and genes listed in Tables 4, 5, 6 and 8.
-
-
19. A method for determining the efficacy of a treatment for stroke in a subject, comprising:
-
(a) measuring the level of one or more biomarkers in a first sample obtained from the subject at a first time point; (b) measuring the level of the one or more biomarkers in a second sample obtained from the subject at a second time point, wherein the subject is under treatment at the second time point; (c) comparing the level of the one or more biomarkers at the first time point to the level of the one or more biomarkers at the second time point; and (d) determining the efficacy of the treatment based on the result of step (c), wherein the one or more biomarkers comprise gene products expressed from genes selected from the group consisting of IL-1α
, IL-1β
, IL-1ra, IL-3, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17, EGF, Eotaxin, FGF-2, FTL-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α
2, IFN-γ
, IP-10, MCP-1, MCP-3, MCD, MIP-1α
, MIP-1β
, PDGF-aa, PGDF-aa bb, RANTES, sCD40L, sIL2-rα
, TNF-α
, TNF-β
, VEGF, NMDA receptor, neuronal specific enolase, GFAP, Apo C-III, MMP-9, D-dimer, CRP, brain natriuretic peptide, S100B and genes listed in Tables 4, 5, 6 and 8.
-
-
20. A kit for detecting biomarkers for stroke in a biological sample, comprising:
-
(a) reagents for detecting a panel of biomarkers for stroke, and (b) a instruction listing the reference range for each of the biomarkers, wherein the panel of biomarkers comprise two or more biomarkers, and wherein the two or more biomarkers comprise gene products expressed from genes selected from the group consisting of IL-1α
, IL-1β
, IL-1ra, IL-3, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17, EGF, Eotaxin, FGF-2, FTL-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α
2, IFN-γ
, IP-10, MCP-1, MCP-3, MCD, MIP-1α
, MIP-1β
, PDGF-aa, PGDF-aa bb, RANTES, sCD40L, sIL2-rα
, TNF-α
, TNF-β
, VEGF, NMDA receptor, neuronal specific enolase, GFAP, Apo C-III, MMP-9, D-dimer, CRP, brain natriuretic peptide, S100B and genes listed in Tables 4, 5, 6 and 8.
-
Specification